Skip to main content

Pfizer Inc(PFE-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low32.83
Day High33.59
Open:33.47
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Reports for Pfizer Inc

News for Pfizer Inc

Select a category then submit the form to load news
Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Motley Fool
2 Dividend Growth Stocks to Buy Right Now
Motley Fool
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
MarketBeat
Flee to Healthcare Stocks if Recession Rears its Head?
Motley Fool
Pfizer Stock: Bear vs. Bull
Newswire.ca
Purpose Life Sciences Creates Strategic Advisory Board, Appoints Jeffrey B. Kindler and Calum MacRae, MD, PhD, to Further Efforts in Revolutionizing Global Clinical Trial Research
Motley Fool
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10
Motley Fool
2 Stocks That Sank Hard on Monday
Newswire.ca
TIME MAGAZINE NAMED GRUPO BIMBO AS THE BEST MEXICAN COMPANY IN THE WORLD
Barchart
Should You Follow Warren Buffett's Lead and Sell HPQ Stock?
MarketBeat
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Newswire.ca
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Motley Fool
This 1 Number May Completely Change Your Opinion About Moderna
Motley Fool
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Motley Fool
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
Motley Fool
Novavax Is a Step Behind, Again. Should You Be Worried?
PR Newswire
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Newswire.ca
Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration
Motley Fool
Wall Street Has Found Its Next High-Flying Stock-Split Stock. Here's Why I'm Not Buying the Hype.
Barchart
Long Straddle Screener Results For September 11th
Motley Fool
2 Dirt Cheap Stocks to Buy With $100
Motley Fool
3 Top Healthcare Stocks to Buy for September
Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Motley Fool
3 Must-Know Tricks for Investing in Big Pharma Stocks
Motley Fool
Could Pfizer Stock Help You Become A Millionaire?
Motley Fool
3 Dividend Stocks That Could Be Ideal Buys for Retirees in September
MarketBeat
3 Stocks to Buy For the COVID Resurgence
Motley Fool
This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?
Motley Fool
Why Novavax Stock Rocketed 10% Higher Today
Motley Fool
3 Forever Stocks to Buy With $100
Newswire.ca
Find Therapeutics Appoints Robert L. Glanzman, M.D., as Chief Medical Officer
Motley Fool
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?
More Pfizer Inc news

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.